Intracellular Generation and Accumulation of Amyloid β-Peptide Terminating at Amino Acid 42
Open accessAbstract
Amyloid beta-peptide (Abeta) is known to accumulate in senile plaques of Alzheimer's disease (AD) patients and is now widely believed to play a major role in the disease. Two populations of peptides occur terminating either at amino acid 40 or at amino acid 42 (Abeta1-40 and Abeta1-42). Alternative N-terminal cleavages produce additional heterogeneity (Abetax-40 and Abetax-42). Peptides terminating at amino acid 42 are believed to be the major player in sporadic AD as well as familial AD (FAD). Whereas the cellular mechanism for the generation of Abeta terminating at amino acid 40 is well understood, very little is known about the cleavage of Abeta after amino acid 42. By using two independent methods we demonstrate intracellular Abeta1-42 as well as Abetax-42 but less Abetax-40 and Abeta1-40 in kidney 293 cells stably transfected with wild type beta-amyloid precursor protein (betaAPP) or the FAD-associated Val/Gly mutation. Moreover, retention of betaAPP within the endoplasmic reticulum (ER) by treatment with brefeldin A does not block the cleavage at amino acid 42 but results in an increased production of all species of Abeta terminating at amino acid 42. This indicates that the cleavage after amino acid 42 can occur within the ER. Treatment of cells with monensin, which blocks transport of (betaAPP) within the Golgi causes a marked accumulation of intracellular Abetax-42 and Abetax-40. Therefore these experiments indicate that the gamma-secretase cleavage of Abeta after amino acid 42 can occur within the ER and later within the secretory pathway within the Golgi. Moreover inhibition of reinternalization by cytoplasmic deletions of betaAPP as well as inhibition of intracellular acidification by NH4Cl does not block intracellular Abeta1-42 or Abetax-42 production.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
FAD mutations cause a relatively greater increase in intracellular compared to secreted Aβ.
“FAD mutations actually cause a relatively greater increase in intracellular compared to secreted Aβ ([202], and unpublished observations).”
From Intraneuronal β-amyloid accumulation and synapse pathology in Alzheimer’s disease (2010) · cites this paper as [202]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 33 · Cited by 303
Research works printed but not linked: 4
- Cotman, C. W., and Pike, C. J. (1994) in Alzheimer's Disease (Terry, R. D., Katzman, R., and Bick, K., eds) pp. 305-315, Raven Press, New York
- Busciglio, J., Gabuzda, D. H., Matsudaira, P., and Yankner, B. A. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 2092-2096
- Citron, M., Diehl, T., Gordon, G., Biere, A., Seubert, P., and Selkoe, D. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 13170 -13175
- Cook, D. G., Sung, J. C., Golde, T. E., Felsenstein, K. M., Wojczyk, B. S., Tanzi, R. E., Trojanowski, J. Q., Lee, V., and Doms, R. W. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 9223-9228
- Authors
- Wild-Bode, C., Yamazaki, T., Capell, A., Leimer, U., Steiner, H., Ihara, Y., & Haass, C.
- Affiliations
- The University of Tokyo (JP)
- Central Institute of Mental Health (DE)
- Corresponding author
- Haass, Christian
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 1997-06
- Volume
- 272
- Issue
- 26
- Pages
- 16085-16088
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W1985325561
- Cited by
- 303
- References
- 33
- Citations by year
- 2025: 3 · 2024: 3 · 2023: 4 · 2022: 4 · 2021: 4 · 2019: 3 · 2018: 4 · 2017: 3 · 2016: 1 · 2015: 4 · 2014: 6 · 2013: 6 · 2012: 8
- FWCI
- 20.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Deutsche Forschungsgemeinschaft (SFB 31 7)
- Japan Society for the Promotion of Science (CREST)
- Core Research for Evolutional Science and Technology
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- amyloid-beta, amyloid-beta 42, Aβ40, gamma-secretase cleavage, Alzheimer's disease, familial Alzheimer's disease, amyloid precursor protein, endoplasmic reticulum, Golgi apparatus, brefeldin A, monensin, secretory pathway
- MeSH terms
- Cell Line, Cyclopentanes, Endoplasmic Reticulum, Humans, Kidney, Amyloid beta-Peptides, Brefeldin A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review